Related Experiment Videos
Hypermethylation of the p15INK4B gene in myelodysplastic syndromes
T Uchida1, T Kinoshita, H Nagai
1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Abstract:
Previous studies have shown that the cyclin-dependent kinase inhibitor (CDKI) genes p15INK4B and p16INK4A are frequently inactivated by genetic alterations in many malignant tumors and that they are candidate tumor-suppressor genes. Although genetic alterations in these genes may be limited to lymphoid malignancies, it has been reported that their inactivation by aberrant methylation of 5' CpG islands may be involved in various hematologic malignancies. In this study, we investigated the p15INK4B and p16INK4A genes to clarify their roles in the pathogenesis of myelodysplastic syndrome (MDS). Southern blotting analysis showed no gross genetic alterations in either of these genes. However, hypermethylation of the 5' CpG island of the p15INK4B gene occurred frequently in patients with MDS (16/32 [50%]). Interestingly, the p15INK4B gene was frequently methylated in patients with high-risk MDS (refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEB-t], and overt leukemia evolved from MDS; 14/18 [78%]) compared with patients with low-risk MDS (refractory anemia [RA] and refractory anemia with ring sideroblast [RARS]; 1/12 [8%]). Furthermore, methylation status of the p15INK4B gene was progressed with the development of MDS in most patients examined. In contrast, none of the MDS patients showed apparent hypermethylation of the p16INK4A gene. These results suggest that hypermethylation of the p15INK4B gene is involved in the pathogenesis of MDS and is one of the important late events during the development of MDS.
Insights
Hypermethylation of the p15INK4B gene is frequently observed in myelodysplastic syndrome (MDS) and progresses with disease development. This epigenetic alteration is implicated in MDS pathogenesis, particularly in high-risk cases.
Area of Science:
- Oncology
- Epigenetics
- Hematology
Background:
- Cyclin-dependent kinase inhibitor (CDKI) genes p15INK4B and p16INK4A are recognized tumor suppressors.
- Aberrant methylation of these genes is implicated in various hematologic malignancies.
- The specific role of p15INK4B and p16INK4A in myelodysplastic syndrome (MDS) pathogenesis requires further investigation.
Purpose of the Study:
- To investigate the role of p15INK4B and p16INK4A gene alterations in the pathogenesis of myelodysplastic syndrome (MDS).
- To determine the frequency and significance of p15INK4B and p16INK4A gene methylation in MDS patients.
Main Methods:
- Southern blotting was used to analyze for gross genetic alterations in p15INK4B and p16INK4A.
- CpG island methylation-specific PCR was employed to assess promoter hypermethylation of p15INK4B and p16INK4A in MDS patients.
- Correlation of methylation status with MDS risk stratification and disease progression was analyzed.
Main Results:
- No gross genetic alterations were detected in p15INK4B or p16INK4A in MDS patients.
- Hypermethylation of the p15INK4B 5' CpG island was observed in 50% of MDS patients (16/32).
- p15INK4B hypermethylation was significantly more frequent in high-risk MDS (78%) compared to low-risk MDS (8%) and correlated with disease progression.
Conclusions:
- Hypermethylation of the p15INK4B gene is a frequent event in MDS pathogenesis.
- p15INK4B methylation appears to be an important late-stage event in MDS development.
- The p16INK4A gene did not show significant hypermethylation in the studied MDS cohort.